Literature DB >> 192142

Comparative study of the antiviral activity of acyl derivatives of 2,2'-anhydro-1-beta-D-arabinofuranosylcytosine and other nucleosides against encephalitis in mice.

S Nishiyama, K Sato, T Yamanaka, J G Moffatt.   

Abstract

Anti-deoxyribonucleic acid virus activities of 3'-O-acyl derivatives of 2,2'-anhydro-1-beta-d-arabinofuranosyl cytosine (cyclo-C) and 1-beta-d-arabinofuranosylcytosine (Ara-C) were evaluated by using an in vivo test system in mice. Among the derivatives tested, 3'-O-decanoyl cyclo-C hydrochloride was the most effective against herpes simplex virus-induced encephalitis in mice when the drug was administered directly into infected brains of mice (target-organ treatment). A comparative study of the treatment of herpetic encephalitis in mice with 3'O-decanoyl cyclo-C and other nucleosides, including Ara-C, 9-beta-d-arabinofuranosyladenine (Ara-A), and 5-iodo-2'-deoxyrudine (IUdR), proved Ara-A to be more efficacious than the other nucleosides, followed by 3'-O-decanoyl cyclo-C, which was more active than Ara-C and IUdR. Administration of 3'-O-acyl cyclo-C's by intraperitoneal injection, however, failed to demonstrate activity against herpetic encephalitis in mice. The antivaccinial activity of 3'-O-decanoyl cyclo-C was also compared with that of other compounds against encephalitis and dermal tail lesions in mice caused by vaccinia virus infection. Interaperitoneally administered 3'-O-decanoyl cyclo-C and Ara-C also showed no significant activity against the diseases. Under these test conditions, N-methylisatin-beta-thiosemicarbazone (Marboran) was the most active compound, followed by Ara-A.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 192142      PMCID: PMC351952          DOI: 10.1128/AAC.11.2.198

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Reactions of 2-acyloxyisobutyryl halides with nucleosides. Synthesis and biological evaluation of some 3"-acyl and 3',5'-diacyl derivatives of 1-beta-D-arabinofuranosylcytosine.

Authors:  E K Hamamura; M Prystasz; J P Verheyden; J G Moffatt
Journal:  J Med Chem       Date:  1976-05       Impact factor: 7.446

2.  On the characteristics of inhibition of deoxyribonucleic acid synthesis by 2,2'-anhydro-1-beta-D-arabinofuranosylcytosine.

Authors:  D Kessel
Journal:  Biochem Pharmacol       Date:  1974-10-01       Impact factor: 5.858

3.  Biochemical and pharmacological studies with 1-beta-D-arabinofuranosylcytosine in man.

Authors:  W A Creasey; R J Papac; M E Markiw; P Calabresi; A D Welch
Journal:  Biochem Pharmacol       Date:  1966-10       Impact factor: 5.858

4.  Synthesis and biologic examination of some derivatives of 2,2'-anhydro-1-(beta-d-arabinofuranosyl)cytosine hydrochloride (NSC-145668).

Authors:  J G Moffatt; E K Hamamura; A F Russell; M Prystasz; J P Verheyden; K Yamaguchi; N Uchida; K Sato; S Nishiyama; O Shiratori; K Katagiri
Journal:  Cancer Chemother Rep       Date:  1974 Jul-Aug

5.  Studies of the enzymatic deamination of cytosine arabinoside. I. Enzyme distribution and species specificity.

Authors:  G W Camiener; C G Smith
Journal:  Biochem Pharmacol       Date:  1965-10       Impact factor: 5.858

6.  2,2'-O-cyclocytidine, an antitumor cytidine analog resistant to cytidine deaminase.

Authors:  A Hoshi; F Kanazawa; K Kuretani; M Saneyoshi; Y Arai
Journal:  Gan       Date:  1971-04

7.  Antiviral activities of acyl derivatives of 2,2'-anhydro-1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosylcytosine in cell culture.

Authors:  K Sato; A Nomura; J G Moffatt
Journal:  Antimicrob Agents Chemother       Date:  1977-02       Impact factor: 5.191

8.  Target-organ treatment of neurotropic virus diseases: efficacy as a chemotherapy tool and comparison of activity of adenine arabinoside, cytosine arabinoside, idoxuridine, and trifluorothymidine.

Authors:  L B Allen; R W Sidwell
Journal:  Antimicrob Agents Chemother       Date:  1972-09       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.